PapersFlow Research Brief
Peptidase Inhibition and Analysis
Research Guide
What is Peptidase Inhibition and Analysis?
Peptidase inhibition and analysis is the study of compounds and methods that block peptidase enzymes to modulate their activity in disease processes, combined with techniques for measuring peptidase function, expression, and inhibition in biological contexts such as cancer and inflammatory conditions.
This field encompasses 132,380 works examining peptidase inhibitors like those targeting matrix metalloproteinases and dipeptidyl peptidases for cancer therapy and airway diseases. Key methods include solid-phase peptide synthesis for inhibitor design and click chemistry for generating selective inhibitors such as peptidotriazoles and cyclooxygenase-2 inhibitors. Analysis techniques focus on protease roles in tumor microenvironments, including PET imaging of stromal cells and high-throughput assays for peptide degradation.
Topic Hierarchy
Research Sub-Topics
Fibroblast Activation Protein Inhibitors
This sub-topic covers the design, synthesis, and therapeutic evaluation of small molecule and antibody-based inhibitors targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts. Researchers study their specificity, pharmacokinetics, and efficacy in preclinical tumor models.
Protease Inhibitors in Cancer Therapy
This sub-topic examines inhibitors of matrix metalloproteinases, cathepsins, and other peptidases involved in tumor invasion, metastasis, and extracellular matrix remodeling. Researchers investigate clinical trial outcomes and resistance mechanisms.
PET Imaging of Tumor Stromal Cells
This sub-topic focuses on radiolabeled probes such as 68Ga-FAPI for positron emission tomography imaging of FAP-expressing stromal cells in various solid tumors. Researchers optimize tracer biodistribution and correlate imaging with therapeutic response.
N-terminal Protein Acetylation in Cancer
This sub-topic explores the role of N-terminal acetyltransferases (NATs) in oncogenic signaling, protein stability, and immune evasion within the tumor microenvironment. Researchers study NAT inhibitors and their impact on cancer cell proliferation.
Immunosuppression by Cancer-Associated Fibroblasts
This sub-topic investigates mechanisms by which cancer-associated fibroblasts suppress T-cell and NK-cell functions through cytokine secretion, metabolite depletion, and checkpoint ligand expression. Researchers develop strategies to reprogram or eliminate immunosuppressive fibroblasts.
Why It Matters
Peptidase inhibition targets proteases driving cancer progression and chronic inflammation, with clinical applications in oncology and respiratory diseases. Slamon et al. (1987) in "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" linked oncogene amplification to poor survival, informing targeted therapies that intersect with protease-modulated tumor microenvironments. The FDA approved BRINSUPRI (brensocatib), a dipeptidyl peptidase 1 (DPP1) inhibitor, for non-cystic fibrosis bronchiectasis, reducing neutrophil serine protease activation and airway inflammation. Egeblad and Werb (2002) in "New functions for the matrix metalloproteinases in cancer progression" detailed MMPs' roles in tumor invasion, supporting inhibitors like those in Kessenbrock et al. (2010) "Matrix Metalloproteinases: Regulators of the Tumor Microenvironment" for stromal targeting.
Reading Guide
Where to Start
"Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" by Merrifield (1963) provides the foundational method for inhibitor synthesis, essential for understanding peptidotriazole and click chemistry approaches in later works.
Key Papers Explained
Merrifield (1963) "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" establishes synthesis basics, enabling Tornøe et al. (2002) "Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides" for azide-alkyne cycloadditions. Bhardwaj et al. (2017) "In situ click chemistry generation of cyclooxygenase-2 inhibitors" applies click methods to enzyme inhibitors. Egeblad and Werb (2002) "New functions for the matrix metalloproteinases in cancer progression" and Kessenbrock et al. (2010) "Matrix Metalloproteinases: Regulators of the Tumor Microenvironment" connect MMP inhibition to cancer applications.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints focus on DPP-IV peptide inhibitors from malt via docking, covalent-reversible designs, and LC-MS assays for degradation. DPP1 inhibitors like brensocatib advance in FDA approvals for bronchiectasis. PELSA assays map interactions in membrane proteins and bacteria.
Papers at a Glance
In the News
FDA Approves BRINSUPRI™ (brensocatib) as the First and ...
BRINSUPRI is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor, designed to inhibit the activation of enzymes (neutrophil serine proteases) in neutrophils that are key drivers of chronic air...
FDA Grants Priority Review to Insmed's Brensocatib for ...
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis, chronic rhinosinusitis with...
BRINSUPRI Marks a Milestone in NCFB Treatment
**Verducatib (BI 1291583)**is an innovative inhibitor of dipeptidyl peptidase 1 (DPP1) and cathepsin C (CatC) that has the potential to enhance symptoms and overall quality of life in patients with...
Breakthrough of DPP-1 Inhibitor in decreasing the ...
According to the CDE website, HSK31858, a Class 1 new drug, was included in the breakthrough therapy designation in 2024 for non-cystic fibrosis bronchiectasis, becoming the first drug in China's a...
FDA Drug Approval Decisions Expected in August 2025
Brensocatib, a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), received Priority Review from the FDA for the treatment of patients with non-cystic fibrosis bronchiectasis.
Code & Tools
PIA allows you to inspect the results of common proteomics spectrum identification search engines, combine them seamlessly and conduct statistical ...
**Abstract**
To facilitate protease research, we present Protease Activity Analysis (PAA). PAA is a Python software package with a collection of tools for analy...
PepFun is a compilation of bioinformatics and chemoinformatics functionalities that are easy to implement and personalize for studying peptides at ...
An automated pipeline that interrogates UniProt or user defined protein database and computes several protein/peptide properties and associated sta...
Recent Preprints
Screening and analysis of malt pentapeptide DPP-IV inhibitory activity
Type 2 diabetes mellitus (T2DM) poses a significant global health burden, with dipeptidyl peptidase-IV (DPP-IV) inhibitors being critical therapeutic targets for its management. Malt, a natural med...
Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories
assembly. Several decades of research were devoted to exploring these precious therapeutic targets, often addressing them with synthetic substrate-based inhibitors to elucidate their biological ro...
A Streamlined High-Throughput LC-MS Assay for Quantifying Peptide Degradation in Cell Culture - PubMed
Peptides are widely used in biomaterials due to their ease of synthesis, ability to signal cells, and modify the properties of biomaterials. A key benefit of using peptides is that they are natural...
Sodium-glucose cotransporter protein-2 (SGLT- ...
Diabetes affects half a billion people worldwide and accounted for 1.5 million deaths in 2016.1 Glucose lowering is a mainstay of treatment.2 In people with type 2 diabetes and higher risks of ...
High-throughput peptide-centric local stability assay extends protein–ligand identification to membrane proteins, tissues and bacteria
Systematic mapping of protein–ligand interactions is essential for understanding biological processes and drug mechanisms. Peptide-centric local stability assay (PELSA) is a powerful tool for detec...
Latest Developments
Recent developments in peptidase inhibition and analysis research include upcoming advanced sessions at the 2026 Proteases, Inhibitors and Therapeutics Conference (GRC), focusing on next-generation inhibitors and protease biology (https://www.grc.org/proteases-inhibitors-and-therapeutics-conference/2026), ongoing exploration of new peptidase inhibitors from sources like spiders without venom (https://www.mdpi.com/1422-0067/27/1/186), and the design of target-specific peptide inhibitors using deep learning and molecular dynamics simulations (https://nature.com/articles/s41467-024-45766-2). Additionally, recent studies have identified novel inhibitory peptides from amphibian skin via peptidomics and molecular simulation (https://doi.org/10.3390/foods14173023), and research is ongoing into covalent cyclic peptide inhibitors of PADI4 (https://www.nature.com/articles/s42004-024-01388-9), reflecting significant progress in peptide-based peptidase inhibition strategies as of early 2026.
Sources
Frequently Asked Questions
What methods are used for synthesizing peptidase inhibitors?
Solid-phase peptide synthesis enables tetrapeptide production as shown by Merrifield (1963) in "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide." Regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions produce peptidotriazoles from terminal alkynes and azides on solid phase, per Tornøe et al. (2002) in "Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides." In situ click chemistry generates cyclooxygenase-2 inhibitors, as in Bhardwaj et al. (2017).
How do matrix metalloproteinases contribute to cancer?
Matrix metalloproteinases regulate the tumor microenvironment by degrading extracellular matrix and promoting invasion, according to Kessenbrock et al. (2010) in "Matrix Metalloproteinases: Regulators of the Tumor Microenvironment." Egeblad and Werb (2002) in "New functions for the matrix metalloproteinases in cancer progression" describe their roles beyond degradation in signaling and immune modulation. These functions position MMPs as targets for peptidase inhibitors in oncology.
What are recent clinical applications of peptidase inhibitors?
Brensocatib, a reversible DPP1 inhibitor, received FDA approval as BRINSUPRI for non-cystic fibrosis bronchiectasis, inhibiting neutrophil serine proteases. Priority FDA review was granted for brensocatib in bronchiectasis and hidradenitis suppurativa. HSK31858 earned breakthrough therapy designation in China for non-cystic fibrosis bronchiectasis.
What tools support peptidase activity analysis?
Protease Activity Analysis (PAA) is a Python package for modular enzyme activity data processing. PIA integrates proteomics search engine results for protein inference and statistical analysis. PepFun provides bioinformatics protocols for peptide sequence, structure, and dataset analysis.
How is peptidase inhibition applied in diabetes research?
Screening of malt pentapeptide for DPP-IV inhibitory activity uses molecular docking like Libdock and Autodock for type 2 diabetes management. DPP-IV inhibitors are key therapeutics targeting glucose regulation in T2DM.
Open Research Questions
- ? How can covalent-reversible peptide-based inhibitors be optimized for specific proteases in clinical settings?
- ? What high-throughput assays best quantify peptide degradation by cell-secreted peptidases in biomaterials?
- ? How does PELSA extend to mapping protein-ligand interactions in membrane proteins and bacterial systems?
- ? Can DPP1 inhibitors like brensocatib be combined with other therapies for broader inflammatory diseases?
- ? What role do fibroblast activation protein inhibitors play in modulating tumor stroma immunosuppression?
Recent Trends
FDA approvals for DPP1 inhibitors like BRINSUPRI (brensocatib) mark clinical progress in bronchiectasis treatment, with priority reviews and breakthrough designations for HSK31858.
Preprints emphasize high-throughput LC-MS for peptide degradation, PELSA for ligand mapping, and DPP-IV peptide screening from malt.
Tools like PAA and PepFun enhance analysis pipelines.
Research Peptidase Inhibition and Analysis with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Peptidase Inhibition and Analysis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers